Literature DB >> 486621

Lithium carbonate in the treatment of schizophrenia and schizo-affective disorder: review and hypothesis.

F T Miller, H Libman.   

Abstract

The success of lithium carbonate in the treatment of manic-depressive illness has led to its use in many other psychiatric disorders. Within this group, schizophrenia and schizo-affective disorder have come under the closest scrutiny. The literature, however, is difficult to reconcile. Conclusions are often contradictory, methodologies confusing, and well-designed studies few in number. In this paper, the authors have attempted to extract common denominators that may prove of value in delineating those symptoms which predict therapeutic response to lithium carbonate.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 486621

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

Review 1.  Requiem for "Schizophrenia".

Authors:  J S Howard
Journal:  Integr Physiol Behav Sci       Date:  1996 Apr-Jun

2.  Common variants in the MKL1 gene confer risk of schizophrenia.

Authors:  Xiong-Jian Luo; Liang Huang; Edwin J van den Oord; Karolina A Aberg; Lin Gan; Zhongming Zhao; Yong-Gang Yao
Journal:  Schizophr Bull       Date:  2014-11-07       Impact factor: 9.306

Review 3.  Lithium for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.